Abyrx and Kairuku have completed a combined $450 million transaction that creates MedEdge Holdings, a new entity designed to drive acquisitions and accelerate commercialization across the surgical products sector. The deal includes a management-led buyout and a significant capital infusion dedicated to acquiring commercial-stage surgical product companies.
MedEdge will use its ownership of Abyrx and Kairuku as the foundation for a broader expansion strategy that aims to streamline how surgeons and hospitals access surgical technologies.
The newly formed holding company intends to integrate Abyrx’s established biomaterials portfolio with Kairuku’s commercial operations software. This combined platform is expected to make it easier for hospitals and surgical teams to source products, manage inventory, and coordinate case support. MedEdge’s leadership aims to reduce administrative complexity across operating rooms while improving access to next-generation biomaterials and commercial tools.
Abyrx develops and commercializes the Montage and Permatage adhesive bone putties, which have been used hundreds of thousands of times in trauma, orthopedic, spine, cardiothoracic, craniomaxillofacial, extremity, and sports medicine procedures. The company plans to leverage its profitable operations to accelerate research and expand its product pipeline.
Kairuku provides a SaaS platform used by medical product manufacturers, sales representatives, and healthcare facilities to manage product availability and case coordination at the point of care. Its system supports inventory tracking, communication, compensation management, and coordination among thousands of representatives who collectively support hundreds of thousands of operating room procedures each year.
MedEdge plans to deploy its new capital toward acquiring and in-licensing additional commercial-stage surgical products, prioritizing those with early market traction and clear advantages over existing technologies. The company expects to add 10 to 15 companies over the coming years, focusing on proprietary, competitively priced products with attractive margins and strong alignment with existing distribution channels.
The companies emphasized that the new structure will enable faster delivery of improved surgical products to healthcare providers while giving manufacturers a more scalable path into the operating room. Dentons served as lead counsel for the transaction, and valuations for Abyrx and Kairuku were not disclosed.
KEY QUOTES
“In founding Abryx, we set a course to consolidate the biomaterials marketplace with a first-in-class polymer technology platform that could address a variety of unmet needs in surgery. Our goal was to create products that were better than the solutions they replaced—products that were easy for surgeons to use, offered at a fair price, and available to every surgeon in every operating room.”
“From the start, we were inspired by a vision to improve biosurgical technologies and the way products are delivered to operating rooms. This new MedEdge Holdings structure allows us to bring better products to surgeons with far less complexity—giving hospitals a simpler, more reliable way to access the technologies they need. It also strengthens our ability to partner with manufacturers that want a more efficient, scalable path into the operating room. I’m grateful to our teams, our sales partners, and the clinicians who have believed in this mission from the beginning.”
John J. Pacifico, Founder And Chief Executive Officer Of Abyrx And Creator Of Kairuku
